These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25497672)

  • 1. RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization.
    Germano A; Rapa I; Volante M; De Francia S; Migliore C; Berruti A; Papotti M; Terzolo M
    Mol Cell Endocrinol; 2015 Feb; 401():105-10. PubMed ID: 25497672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.
    Hermsen IG; Fassnacht M; Terzolo M; Houterman S; den Hartigh J; Leboulleux S; Daffara F; Berruti A; Chadarevian R; Schlumberger M; Allolio B; Haak HR; Baudin E
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1844-51. PubMed ID: 21470991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.
    Hescot S; Paci A; Seck A; Slama A; Viengchareun S; Trabado S; Brailly-Tabard S; Al Ghuzlan A; Young J; Baudin E; Lombès M
    Horm Cancer; 2014 Oct; 5(5):312-23. PubMed ID: 25026941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer.
    Volante M; Terzolo M; Fassnacht M; Rapa I; Germano A; Sbiera S; Daffara F; Sperone P; Scagliotti G; Allolio B; Papotti M; Berruti A
    Clin Cancer Res; 2012 Jun; 18(12):3452-61. PubMed ID: 22547773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Practical use of o,p'DDD in adrenocortical carcinoma].
    Bacchetta J; Droz JP
    Bull Cancer; 2005 Mar; 92(3):273-9. PubMed ID: 15820922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma.
    Baudin E; Pellegriti G; Bonnay M; Penfornis A; Laplanche A; Vassal G; Schlumberger M
    Cancer; 2001 Sep; 92(6):1385-92. PubMed ID: 11745214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results.
    Faggiano A; Leboulleux S; Young J; Schlumberger M; Baudin E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):110-3. PubMed ID: 16402938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
    Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A
    Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines.
    Germano A; Rapa I; Volante M; Lo Buono N; Carturan S; Berruti A; Terzolo M; Papotti M
    Mol Cell Endocrinol; 2014 Jan; 382(1):1-7. PubMed ID: 24018612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of mitotane on viability, steroidogenesis and gene expression in NCI‑H295R adrenocortical cells.
    Lehmann TP; Wrzesiński T; Jagodziński PP
    Mol Med Rep; 2013 Mar; 7(3):893-900. PubMed ID: 23254310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible mechanism and treatment of o,p'DDD-induced hypercholesterolaemia.
    Maher VM; Trainer PJ; Scoppola A; Anderson JV; Thompson GR; Besser GM
    Q J Med; 1992 Sep; 84(305):671-9. PubMed ID: 1480741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of o,p'DDD therapy on endogenous ACTH concentrations in dogs with hypophysis-dependent hyperadrenocorticism.
    Nelson RW; Feldman EC; Shinsako J
    Am J Vet Res; 1985 Jul; 46(7):1534-7. PubMed ID: 2992329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. o,p'DDD therapy in invasive adrenocortical carcinoma.
    Becker D; Schumacher OP
    Ann Intern Med; 1975 May; 82(5):677-9. PubMed ID: 1137262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
    Doghman M; Lalli E
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hormone-producing adrenocortical cancer with o,p'DDD and streptozocin.
    Eriksson B; Oberg K; Curstedt T; Hemmingsson A; Johansson H; Lindh E; Lindgren PG; Thuomas KA; Wilander E; Akerström G
    Cancer; 1987 Apr; 59(8):1398-403. PubMed ID: 2949824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma.
    Cusato J; De Francia S; Allegra S; Carrella S; Pirro E; Piccione FM; De Martino F; Ferrero A; Daffara FC; Terzolo M; Berruti A; Di Carlo F; Tampellini M; D'Avolio A
    J Pharm Pharmacol; 2017 Nov; 69(11):1524-1530. PubMed ID: 28809444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management.
    Boulate G; Amazit L; Naman A; Seck A; Paci A; Lombes A; Pussard E; Baudin E; Lombes M; Hescot S
    Int J Oncol; 2019 Jun; 54(6):2149-2156. PubMed ID: 30942448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Cushing's syndrome due to ectopic adrenocorticotropin secretion with 1,ortho-1, para'-dichloro-diphenyl-dichloro-ethane: findings in 23 patients from a single center.
    Donadille B; Groussin L; Waintrop C; Abbas H; Tenenbaum F; Dugué MA; Coste J; Bertagna X; Bertherat J
    J Clin Endocrinol Metab; 2010 Feb; 95(2):537-44. PubMed ID: 20061433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological Effects of EF24, a Curcumin Derivative, Alone or Combined with Mitotane in Adrenocortical Tumor Cell Lines.
    Bertazza L; Barollo S; Mari ME; Faccio I; Zorzan M; Redaelli M; Rubin B; Armanini D; Mian C; Pezzani R
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31212829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells.
    Hescot S; Slama A; Lombès A; Paci A; Remy H; Leboulleux S; Chadarevian R; Trabado S; Amazit L; Young J; Baudin E; Lombès M
    Endocr Relat Cancer; 2013 Jun; 20(3):371-81. PubMed ID: 23696597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.